ulbi20260723_8k.htm
false 0000875657 0000875657 2026-07-23 2026-07-23
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
July 23, 2026
Date of Report (Date of Earliest Event Reported)
 
ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)
 
Delaware
000-20852
16-1387013
(State of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
2000 Technology ParkwayNewarkNew York 14513
(Address of principal executive offices) (Zip Code)
 
(315332-7100
(Registrant’s telephone number, including area code)
 
Securities registered pursuant to Section 12(b) of the Act:
 
 
Title of each class
 
Trading Symbol
 
Name of each exchange on which registered
Common Stock, $0.10 par value per share
 
ULBI
 
 NASDAQ Stock Market
    
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company  
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

 
Item 5.07         Submission of Matters to a Vote of Security Holders.
 
On July 22, 2026, Ultralife Corporation (“the Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Only stockholders of record at the close of business on May 28, 2026 (the “Record Date”) were entitled to vote at the Annual Meeting. As of the Record Date, there were 16,656,669 shares of common stock outstanding and entitled to vote, of which 13,980,794 (83.93%) were present in person or by proxy, representing a quorum. The results of stockholder voting on the proposals presented were as follows:
 
1. The Company’s stockholders elected five Directors, all of whom constitute the Company’s entire Board of Directors, to serve for a term of one year and until their successors are duly elected and qualified. The number of shares that (i) voted for the election of each Director, (ii) withheld authority to vote for each Director, and (iii) were broker non-votes, are set forth in the table below.
 
Director
For
Withheld
Broker Non-Votes
 
 
 
 
Michael E. Manna
11,065,320
 215,149
2,700,325
Janie Goddard
10,260,448
1,020,021
2,700,325
Thomas L. Saeli
11,044,346
  236,123
2,700,325
Robert W. Shaw II
11,044,375
  236,094
2,700,325
Bradford T. Whitmore
10,912,209
  368,260
2,700,325
 
2. The Company’s stockholders ratified the selection of the Company’s independent registered public accounting firm as WithumSmith+Brown, PC for 2026. The number of shares that (i) voted for the ratification of the accounting firm, (ii) voted against the ratification, and (iii) abstained from the vote are set forth in the table below.
 
For
Withheld
Abstain
 
 
 
13,830,508
137,166
13,120
 
3. The Company’s shareholders approved an advisory resolution on executive compensation. The number of shares that (i) voted for the resolution, (ii) voted against the resolution, (iii) abstained from the vote, and (iv) were broker non-votes, are set forth in the table below.
 
For
Against
Abstain
Broker Non-Votes
 
 
 
 
10,970,705
245,370
64,394
2,700,325
                                                                 
4. The Company’s shareholders indicated their preference, on a non-binding advisory basis, that the frequency of future advisory votes on executive compensation be “3 Years”. The number of shares that (i) voted for 1 Year, (ii) voted for 2 Years, (iii) voted for 3 Years, and (iv) abstained from the vote, are set forth in the table below.
 
1 Year
2 Years
3 Years
Abstain
 
 
 
 
2,576,450
109,411
8,554,151
40,457
                                                   
In consideration of the voting results of the Annual Meeting and other factors, the Board of Directors has determined that the frequency of future advisory votes on executive compensation will be three years.
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: July 23, 2026
 
ULTRALIFE CORPORATION
 
 
 
 
 
 
 
By:
/s/ Philip A. Fain
 
 
Philip A. Fain
 
 
Chief Financial Officer and Treasurer